BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

928 related articles for article (PubMed ID: 25666752)

  • 1. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
    Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
    Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
    Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
    Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
    Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
    J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
    Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTORC2 is required for proliferation and survival of TSC2-null cells.
    Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
    Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
    Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
    Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
    Misra UK; Pizzo SV
    PLoS One; 2012; 7(12):e51735. PubMed ID: 23272152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
    Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
    Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
    Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA
    Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts.
    Shu L; Houghton PJ
    Mol Cell Biol; 2009 Sep; 29(17):4691-700. PubMed ID: 19564418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells.
    Rosario FJ; Kanai Y; Powell TL; Jansson T
    J Physiol; 2013 Feb; 591(3):609-25. PubMed ID: 23165769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.
    Toschi A; Lee E; Gadir N; Ohh M; Foster DA
    J Biol Chem; 2008 Dec; 283(50):34495-9. PubMed ID: 18945681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
    Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
    J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
    Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM
    Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.